PEDIATRICS Vol. 58 No. 3 September 1976, pp. 412-422
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moore, D. C.
Right arrow Articles by Kelley, V. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moore, D. C.
Right arrow Articles by Kelley, V. C.

Studies of Anabolic Steroids: V. Effect of Prolonged Oxandrolone Administration on Growth in Children and Adolescents With Uncomplicated Short Stature

Dan C. Moore M.D.1, Diana S. Tattoni M.D.1, George A. Limbeck M.D.1, R. H.A. Ruvelcaba M.D.1, Diana S. Lindner M.D.1, Frank J. Gareis M.D.1, Saad Al-Agba M.D.1, and Vincent C. Kelley M.D., Ph.D.1

1 Division of Pediatric Endocrinology and Metabolism, University of Washington School of Medicine, and Children's Orthopedic Hospital and Medical Center, Seattle, Washington, the Division of Pediatric and Metabolic Disorders, University of California, Irvine, and Children's Hospital of Orange County, Orange, California

A total of 130 patients with uncomplicated short stature (4 to 17 years of age) were treated with oxandrolone, 0.25 mg/kg/day, for up to four years. Oxandrolone therapy resulted in a two-fold increase in mean growth velocity in the first six months of therapy and was an effective growth stimulant for the full four-year period. There was no overall adverse effect of oxandrolone on post-treatment mean growth velocity or on skeletal maturation relative to height gain. There were 37 patients with greater increase in height age than bone age and 22 patients with greater increase in bone age than height age. Assessment of the contribution of oxandrolone therapy to the latter group is difficult because of inadequate methodology and the wide variation in individual growth patterns. Taken in their entirety, the data suggest that oxandrolone is useful in the prolonged treatment of uncomplicated short stature and is not associated with undesirable acceleration of skeletal maturation.

Submitted on August 28, 1975
Accepted on November 25, 1975




This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
A. Vottero, S. Pedori, M. Verna, B. Pagano, M. Cappa, S. Loche, S. Bernasconi, and L. Ghizzoni
Final Height in Girls with Central Idiopathic Precocious Puberty Treated with Gonadotropin-Releasing Hormone Analog and Oxandrolone
J. Clin. Endocrinol. Metab., April 1, 2006; 91(4): 1284 - 1287.
[Abstract] [Full Text] [PDF]